Due to the special nature of medicines, returns and exchanges are not supported.
Final delivery from the nearest overseas warehous NEW

Mekinist Tablets

MEKINIST™ is indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma that harbors BRAFV600E and V600K mutations as detected by an FDA-approved test. MEKINIST, in combination with dabrafenib, is indicated for the treatment of patients with unresectable or metastatic melanoma that harbors BRAFV600E and V600K mutations as detected by an FDA-approved test.
Trametinib is a reversible inhibitor of mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 activation and MEK1 and MEK2 kinase activity, which can inhibit tumor cell growth.

Brand: pill Categories:

Share: